Rafal Iwasiow, Ph.D., was named Vice President of Science, Innovation and Technology for OraSure in February 2023. In this role, he leads an enterprise-wide interdisciplinary Research and Development team that includes expertise for product industrial design, chemistry development, assay development, clinical service development, and software engineering. Additionally, he has responsibilities for scientific and clinical affairs, as well as customer technical support. Dr. Iwasiow joined OraSure subsidiary DNA Genotek in 2006 as a Research and Development Scientist and has held roles of increasing responsibility since that time. He has contributed significantly to the company's patent portfolio in numerous areas, including nucleic acid stabilization methods, and physical sample collection devices. Under Dr. Iwasiow’s leadership, the Research and Development team contributed to successful 510(k) clearances of the Oragene®•Dx and OraCollect®•Dx collection devices, the first non-invasive DNA collection device cleared by the FDA, as well as de novo authorization of the Omnigene® GUT•Dx collection device, the first self-collection gut microbiome device. Prior to joining the Company, Dr. Iwasiow completed a post-doctoral fellowship at the National Research Council of Canada in the areas of neurogenesis/neuroprotection. He holds a Ph.D. in Cellular and Molecular Medicine from the University of Ottawa.